Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 3/20 | 0.51 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.51 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22277790 | 0.89 | DHFR (0.51) | DHFRP2RX3P2RX2MEN1SLC22A1 | |
| SCHEMBL22277338 | 0.89 | DHFR (0.48) | DHFRP2RX3P2RX2 | |
| SCHEMBL22277334 | 0.83 | DHFR (0.51) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| SCHEMBL22277340 | 0.83 | DHFR (0.47) | DHFRP2RX3P2RX2 | |
| SCHEMBL22277341 | 0.83 | DHFR (0.50) | DHFRP2RX3P2RX2 | |
| SCHEMBL22277789 | 0.81 | DHFR (0.49) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| SCHEMBL22277745 | 0.81 | DHFR (0.48) | DHFR | |
| SCHEMBL22277786 | 0.75 | DHFR (0.52) | DHFRP2RX3P2RX2 | |
| SCHEMBL20284270 | 0.73 | P2RX3 (0.52) | P2RX3P2RX2 | |
| SCHEMBL22277735 | 0.73 | DHFR (0.50) | DHFRP2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591315-B2 | Substituted pyrazole-pyrimidines, variants thereof, and uses therefore | MERCK SHARP & DOHME LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210171505-A1 | SUBSTITUTED PYRAZOLE-PYRIMIDINES, VARIANTS THEREOF, AND USES THEREFORE | Afferent Pharmaceuticals, Inc. (US) | 2021-06-10 | — | — | US | disclosed |
| US-10988460-B2 | Substituted pyrazole-pyrimidines, variants thereof, and uses therefore | Afferent Pharmaceuticals, Inc. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200239451-A1 | SUBSTITUTED PYRAZOLE-PYRIMIDINES, VARIANTS THEREOF, AND USES THEREFORE | Afferent Pharmaceuticals, Inc. (US) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591315-B2 | Substituted pyrazole-pyrimidines, variants thereof, and uses therefore | P2RX3, P2RX5, P2RX1 | DHFR 1898/4885P2RX3 1/4885P2RX2 4/4885 |
| US-20210171505-A1 | SUBSTITUTED PYRAZOLE-PYRIMIDINES, VARIANTS THEREOF, AND USES THEREFORE | P2RX3, P2RX5, P2RX1 | DHFR 1898/4885P2RX3 1/4885P2RX2 4/4885 |
| US-20200239451-A1 | SUBSTITUTED PYRAZOLE-PYRIMIDINES, VARIANTS THEREOF, AND USES THEREFORE | P2RX3, P2RX5, P2RX1 | DHFR 2085/4885P2RX3 1/4885P2RX2 4/4885 |
| US-10988460-B2 | Substituted pyrazole-pyrimidines, variants thereof, and uses therefore | P2RX3, P2RX5, P2RX1 | DHFR 2085/4885P2RX3 1/4885P2RX2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.